Search Results - N. M. Danilov

Refine Results
  1. 1
    Restenosis risk factors after coronary stenting in metabolic syndrome patients

    Restenosis risk factors after coronary stenting in metabolic syndrome patients by N. M. Danilov, T. T. Gorgadze, A. P. Savchenko, I. E. Chazova

    Published 2007-04-01

    This review is devoted to coronary restenosis after stent implantation in metabolic syndrome (MS) patients. It is known that some clinical factors increase restenosis risk, first of all, diabetes mellitus. Recently, MS has also been regarded as a pathology enhancing coronary restenosis risk. Certain...

    Full description

    Get full text
    Article

    Save to List
    Saved in:
  2. 2
    STRUCTURAL CHANGES OF THE PULMONARY ARTERIES AFTER BALLOON PULMONARY ANGIOPLASTY IN PATIENTS WITH CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION

    STRUCTURAL CHANGES OF THE PULMONARY ARTERIES AFTER BALLOON PULMONARY ANGIOPLASTY IN PATIENTS WITH CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION by S. Y. Yarovoy, N. M. Danilov, Yu. G. Matchin, I. E. Chazova

    Published 2020-12-01

    Aim. To assess the effect of balloon pulmonary angioplasty (BPA) on structural parameters of the pulmonary arteries in inoperable patients with chronic thromboembolic pulmonary hypertension (CTEPH).Materials and methods. The study included 21 patients with an inoperable form of CTEPH. Assessment of...

    Full description

    Get full text
    Article

    Save to List
    Saved in:
  3. 3
    CLINICAL CASE OF SUCCESSFUL 10-YEAR AMBRIZENTAN TREATMENT OF THE PATIENT WITH IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION

    CLINICAL CASE OF SUCCESSFUL 10-YEAR AMBRIZENTAN TREATMENT OF THE PATIENT WITH IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION by T. V. Martynyuk, M. A. Saidova, N. M. Danilov, V. K. Lazutkina, I. Ye. Chazova

    Published 2015-12-01

    Idiopathic pulmonary arterial hypertension (IPAH) is a rare cardiovascular disease of unknown etiology, characterized by pulmonary vascular resistance (PVR) and pulmonary artery pressure (PAP) increase due to pronounced remodeling of small pulmonary arteries and arterioles, with progressive deterior...

    Full description

    Get full text
    Article

    Save to List
    Saved in:
  4. 4
    COVID-19 pandemic challenges: on the way to overcome obstacles in realization of PAH-specific therapy treatment goals

    COVID-19 pandemic challenges: on the way to overcome obstacles in realization of PAH-specific therapy treatment goals by E. A. Rezukhina, I. Z. Korobkova, N. M. Danilov, V. V. Gramovich, T. V. Martynyuk

    Published 2021-11-01

    Our observation demonstrates a case of a 40-year-old female with idiopathic pulmonary arterial hypertension World Health Organization functional class III, who was admitted to NMRC of Cardiology repeatedly due to disease progression including dyspnea worsening and exercise tolerance decrease after p...

    Full description

    Get full text
    Article

    Save to List
    Saved in:
  5. 5
    THE RESULTS OF LONG-TERM PAH-SPECIFIC MONOTHERAPY WITH BOSENTAN IN PATIENTS WITH IDIOPATHIC PULMONARY HYPERTENSION

    THE RESULTS OF LONG-TERM PAH-SPECIFIC MONOTHERAPY WITH BOSENTAN IN PATIENTS WITH IDIOPATHIC PULMONARY HYPERTENSION by V. M. Paramonov, T. V. Martynyuk, N. M. Danilov, Yu. G. Matchin, I. Ye. Chazova

    Published 2016-06-01

    Objective. To evaluate the dynamics of clinical and functional status, the parameters of central hemodynamics and tolerability of bosentan therapy lasting more than 12 months in patients with idiopathic pulmonary hypertension (IPAH). Materials and methods. In the study we included 20 IPAH non-respon...

    Full description

    Get full text
    Article

    Save to List
    Saved in:
  6. 6
    CLINICAL CASE: THERAPY WITH SILDENAFIL IN THE TREATMENT OF IDIOPATHIC PULMONARY HYPERTENSION

    CLINICAL CASE: THERAPY WITH SILDENAFIL IN THE TREATMENT OF IDIOPATHIC PULMONARY HYPERTENSION by Z. S. Valieva, Z. H. Dadacheva, T. V. Martynyuk, N. M. Danilov, M. A. Saidova, I. Ye. Chazova

    Published 2015-12-01

    The patient with the verified diagnosis of idiopathic pulmonary hypertension, negative acute vasoreactivity testing by RHC, functional class III (WHO) was treated by phosphodiesterase type 5 inhibitor sildenafil. After one year there was achieved the significant improvement of the functional and hem...

    Full description

    Get full text
    Article

    Save to List
    Saved in:
  7. 7
    SUCCESSFUL TREATMENT OF INOPERABLE THROMBOEMBOLIC PULMONARY HYPERTENSION PATIENT WITH SILDENAFIL IN HIGH DOSES

    SUCCESSFUL TREATMENT OF INOPERABLE THROMBOEMBOLIC PULMONARY HYPERTENSION PATIENT WITH SILDENAFIL IN HIGH DOSES by Z. H. Dadacheva, T. V. Martynyuk, M. A. Saidova, N. M. Danilov, K. V. Mershin, I. Ye. Chazova

    Published 2014-12-01

    The currentguidelines on chronic thromboembolic pulmonary hypertension (CTEPH) treatment consider pulmonary thrombendarterectomy as the first therapy choice. In case of inoperability due to severe patient's condition, distal lesions of pulmonary vessels, extremely high pulmonary vascular resist...

    Full description

    Get full text
    Article

    Save to List
    Saved in:
  8. 8
    Assessment of the sensitivity of diagnostic methods in detecting hemodynamically significant renal artery stenoses

    Assessment of the sensitivity of diagnostic methods in detecting hemodynamically significant renal artery stenoses by A. M. Erkenova, N. M. Danilov, Yu. G. Matchin, V. V. Kushnir, S. A. Gaman, I. E. Chazova

    Published 2024-05-01

    Objective. Assessment of renal artery stenosis significance in patients with resistant arterial hypertension using non-invasive diagnostic methods and to compare them with the results of selective angiography and methods of physiological assessment of renal artery stenoses.Materials and methods. Pro...

    Full description

    Get full text
    Article

    Save to List
    Saved in:
  9. 9
    CLINICAL AND HEMODYNAMIC PROFILE AND NEUROHORMONAL INDICATORS IN PATIENTS WITH IDIOPATHIC PULMONARY HYPERTENSION, DEPENDING ON VASOREACTIVITY RESERVE OF PULMONARY ARTERIES

    CLINICAL AND HEMODYNAMIC PROFILE AND NEUROHORMONAL INDICATORS IN PATIENTS WITH IDIOPATHIC PULMONARY HYPERTENSION, DEPENDING ON VASOREACTIVITY RESERVE OF PULMONARY ARTERIES by V. M. Paramonov, T. V. Martynyuk, Z. H. Dadacheva, N. M. Danilov, V. P. Masenko, I. Ye. Chazova

    Published 2016-03-01

    Clinical and hemodynamic profile and neurohormonal indicators in patients with idiopathic pulmonary hypertension, depending on vasoreactivity reserve of pulmonary arteries. Objective: the main objective of our research work was an evaluation of clinical and hemodynamic profile, neurohormonal indicat...

    Full description

    Get full text
    Article

    Save to List
    Saved in:
  10. 10
    Possibilities of long-term effective treatment of idiopathic pulmonary arterial hypertension by replacing sildenafil with riociguat and using sequential combination therapy: case report

    Possibilities of long-term effective treatment of idiopathic pulmonary arterial hypertension by replacing sildenafil with riociguat and using sequential combination therapy: case r... by S. A. Musashaykhova, Z. S. Valieva, A. K. Osokina, I. Z. Korobkova, V. V. Gramovich, N. M. Danilov, T. V. Martynyuk

    Published 2022-12-01

    Modern pathogenetic therapy of idiopathic pulmonary arterial hypertension (IPAH), a severe life-threatening cardiovascular disease of unknown etiology, leads to a positive clinical effect due to reverse remodeling of the vessels of the microvasculature of the lungs. Highly effective drugs of specifi...

    Full description

    Get full text
    Article

    Save to List
    Saved in:
  11. 11
    The first Russian experience with the endothelin 1 receptor inhibitor traclir used in patients with pulmonary hypertension associated with systemic connective tissue diseases

    The first Russian experience with the endothelin 1 receptor inhibitor traclir used in patients with pulmonary hypertension associated with systemic connective tissue diseases by Aleksandr Vitalyevich Volkov, T V Martynyuk, N N Yudkina, N M Danilov, T M Reshetnyak, I E Chazova, E L Nasonov

    Published 2011-12-01

    Objective: to study the efficacy and safety of the endothelin 1 receptor inhibitor traclir in patients with pulmonary hypertension (PH) asso ciated with systemic connective tissue diseases. Subjects and methods. The study include...

    Full description

    Get full text
    Article

    Save to List
    Saved in:
  12. 12
    COMPLICATED CLINICAL CASE: CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION IN PATIENT WITH RECIDIVOUS CARDIAC MYXOMA

    COMPLICATED CLINICAL CASE: CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION IN PATIENT WITH RECIDIVOUS CARDIAC MYXOMA by A. M. Zykova, O. A. Arkhipova, T. V. Martynyuk, A. Y. Demchenkova, N. M. Danilov, I. Z. Korobkova, I. Ye. Chazova

    Published 2018-03-01

    The clinical case demonstrates the difficulties of differential diagnosis and the determination of treatment tactics in a patient with chronic thromboembolic pulmonary hypertension, recidivous cardiac myxoma and radiographic pattern of dissemination in lung tissue.

    Get full text
    Article

    Save to List
    Saved in:
  13. 13
    DIAGNOSIS AND MANAGEMENT OF PULMONARY EMBOLISM EURASIAN ASSOCIATION OF CARDIOLOGY (EAC) CLINICAL PRACTICE GUIDELINES (2021)

    DIAGNOSIS AND MANAGEMENT OF PULMONARY EMBOLISM EURASIAN ASSOCIATION OF CARDIOLOGY (EAC) CLINICAL PRACTICE GUIDELINES (2021) by E. P. Panchenko, T. V. Balahonova, N. M. Danilov, A. L. Komarov, E. S. Kropachyova, M. A. Saidova, O. O. Shahmatova, I. S. Yavelov

    Published 2021-03-01

    Disclaimer. The EAC Guidelines represent the views of the EAC, and were produced after careful consideration of the scientific and medical knowledge, and the evidence available at the time of their publication. The EAC is not responsible in the event of any contradiction, discrepancy, and/or ambigui...

    Full description

    Get full text
    Article

    Save to List
    Saved in:
  14. 14
    CLINICAL CASE: COMBINATION THERAPY WITH BOSENTAN AND SILDENAFIL IN THE TREATMENT OF IDIOPATHIC PULMONARY HYPERTENSION

    CLINICAL CASE: COMBINATION THERAPY WITH BOSENTAN AND SILDENAFIL IN THE TREATMENT OF IDIOPATHIC PULMONARY HYPERTENSION by V. V. Bystrov, O. A. Arkhipova, T. V. Martynyuk, M. A. Saidova, O. V. Stukalova, N. M. Danilov, T. A. Sakhnova, I. Ye. Chazova

    Published 2014-12-01

    The patient with the verified diagnosis of idiopathic pulmonary hypertension, functional class III (WHO) was treated by anticoagulants, diuretics, calcium channel blocker. After one year of adding endothelin receptor antagonist bosentan there was noticed the negative dynamic with right heart chamber...

    Full description

    Get full text
    Article

    Save to List
    Saved in:
  15. 15
    Eurasian Association of Cardiology (EAC)/ Russian society of somnologists (RSS) guidelines for the diagnosis and treatment of obstructive sleep apnea in patients with cardiovascular diseases (2024)

    Eurasian Association of Cardiology (EAC)/ Russian society of somnologists (RSS) guidelines for the diagnosis and treatment of obstructive sleep apnea in patients with cardiovascula... by A. Yu. Litvin, I. E. Chazova, E. M. Elfimova, A. V. Pevzner, M. G. Poluektov, N. M. Danilov, O. O. Mikhailova, A. V. Aksenova

    Published 2024-10-01

    The aim of this guideline is to assist physicians in the management of patients with cardiovascular pathology and obstructive sleep-disordered breathing.   The article consists data on diagnostic tactics for patients with possible sleep-breathing disorders, describes the basic principles of obstruct...

    Full description

    Get full text
    Article

    Save to List
    Saved in:
  16. 16
    Russian consensus: balloon pulmonary angioplasty in treatment of chronic thromboembolic pulmonary hypertension

    Russian consensus: balloon pulmonary angioplasty in treatment of chronic thromboembolic pulmonary hypertension by N. M. Danilov, Yu. G. Matchin, D. S. Grankin, N. V. Marukyan, S. Y. Yarovoy, N. A. Androsov, E. M. Elfimova, Yu. V. Danilushkin, T. V. Martynyuk, K. V. Mershin, A. G. Edemskiy, A. M. Chernyavskiy, A. Yu. Litvin, I. E. Chazova

    Published 2025-03-01

    For a long time, the only method of revascularization in patients with chronic thromboembolic pulmonary hypertension (CTEPH) was pulmonary thromboendarterectomy from the branches of pulmonary artery. Transluminal balloon pulmonary angioplasty (BPA), as an alternative treatment option for inoperable...

    Full description

    Get full text
    Article

    Save to List
    Saved in:
  17. 17
    Eurasian guidelines for the diagnosis and treatment of pulmonary hypertension (2023)

    Eurasian guidelines for the diagnosis and treatment of pulmonary hypertension (2023) by I. E. Chazova, T. V. Martynyuk, A. A. Shmalts, V. V. Gramovich, N. M. Danilov, T. N. Veselova, I. Z. Korobkova, A. Sh. Sarybaev, O. V. Stukalova, V. A. Azizov, O. L. Barbarash, A. S. Galyavich, S. V. Gorbachevsky, E. A. Medvedeva, Yu. G. Matchin, M. A. Mukarov, S. N. Nakonechnikov, E. V. Filippov, I. E. Chernogrivov

    Published 2024-03-01

    .

    Get full text
    Article

    Save to List
    Saved in:
  18. 18
    Eurasian clinical guidelines for the diagnosis and treatment of secondary (symptomatic) forms of arterial hypertension (2022)

    Eurasian clinical guidelines for the diagnosis and treatment of secondary (symptomatic) forms of arterial hypertension (2022) by I. E. Chazova, N. M. Chikhladze, N. V. Blinova, Zh. E. Belaya, N. M. Danilov, E. M. Elfimova, A. Yu. Litvin, L. Ya. Rozhinskaya, N. Yu. Sviridenko, M. Yu. Shvetsov, V. A. Azizov, E. A. Grigorenko, N. P. Mit’kovskaja, I. I. Mustafaev, A. G. Polupanov, A. Sh. Sarybaev, G. A. Hamidullaeva

    Published 2023-03-01

    Disclaimer. The EAC Guidelines represent the views of the EAC, and were produced after careful consideration of the scientific and medical knowledge, and the evidence available at the time of their publication. The EAC is not responsible in the event of any contradiction, discrepancy, and/or ambigui...

    Full description

    Get full text
    Article

    Save to List
    Saved in:
  19. 19
    Eurasian guidelines for the diagnosis and treatment of pulmonary hypertension associated with congenital heart defects in adults (2021)

    Eurasian guidelines for the diagnosis and treatment of pulmonary hypertension associated with congenital heart defects in adults (2021) by I. E. Chazova, S. V. Gorbachevskij, T. V. Martynyuk, A. A. Shmal’c, Z. S. Valieva, I. Yu. Baryshnikova, L. A. Glushko, V. V. Gramovich, V. A. Azizov, T. N. Veselova, N. M. Danilov, P. A. Zelveyan, S. N. Ivanov, I. V. Lazareva, Yu. G. Matchin, M. A. Mukarov, S. N. Nakonechnikov, A. Sh. Sarybaev, O. V. Stukalova, S. V. Shalaev

    Published 2022-05-01

    .

    Get full text
    Article

    Save to List
    Saved in:
  20. 20
    2020 Clinical practice guidelines for Pulmonary hypertension, including chronic thromboembolic pulmonary hypertension

    2020 Clinical practice guidelines for Pulmonary hypertension, including chronic thromboembolic pulmonary hypertension by S. N. Avdeev, O. L. Barbarash, A. E. Bautin, A. V. Volkov, T. N. Veselova, A. S. Galyavich, N. S. Goncharova, S. V. Gorbachevsky, N. M. Danilov, A. A. Eremenko, T. V. Martynyuk, O. M. Moiseeva, M. A. Saidova, V. B. Sergienko, M. A. Simakova, O. V. Stukalova, I. E. Chazova, A. M. Chernyavsky, S. V. Shalaev, A. A. Shmalts, N. A. Tsareva

    Published 2022-01-01

    Russian Society of Cardiology (RSC)With the participation: Association of Cardiovascular Surgeons of Russia, Russian Respiratory Society, Federation of Anesthesiologists and Resuscitators, Association of Rheumatologists of Russia, National Congress of Radiation Diagnosticians.

    Get full text
    Article

    Save to List
    Saved in:

Search Tools: